Travere Therapeutics, Inc. TVTX Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s accrued liabilities, current?
- Travere Therapeutics, Inc. (TVTX) reported accrued liabilities, current of $104.41M in Q1 2026.
- How has Travere Therapeutics, Inc.'s accrued liabilities, current changed year-over-year?
- Travere Therapeutics, Inc.'s accrued liabilities, current increased by 35.4% year-over-year, from $77.11M to $104.41M.
- What is the long-term trend for Travere Therapeutics, Inc.'s accrued liabilities, current?
- Over 5 years (2020 to 2025), Travere Therapeutics, Inc.'s accrued liabilities, current has grown at a 17.3% compound annual growth rate (CAGR), from $56.79M to $126.04M.